| pubmed-article:15386824 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15386824 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:15386824 | lifeskim:mentions | umls-concept:C0332307 | lld:lifeskim |
| pubmed-article:15386824 | lifeskim:mentions | umls-concept:C0007785 | lld:lifeskim |
| pubmed-article:15386824 | lifeskim:mentions | umls-concept:C0011881 | lld:lifeskim |
| pubmed-article:15386824 | lifeskim:mentions | umls-concept:C0012367 | lld:lifeskim |
| pubmed-article:15386824 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:15386824 | lifeskim:mentions | umls-concept:C0085826 | lld:lifeskim |
| pubmed-article:15386824 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:15386824 | pubmed:dateCreated | 2005-1-10 | lld:pubmed |
| pubmed-article:15386824 | pubmed:abstractText | To determine whether diabetic nephropathy is a risk factor for silent cerebral infarction and whether antiplatelet drug dilazep dihydrochloride decreases the occurrence of silent cerebral infarction in type 2 diabetes patients with microalbuminuria. | lld:pubmed |
| pubmed-article:15386824 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15386824 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15386824 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15386824 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15386824 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15386824 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15386824 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15386824 | pubmed:issn | 1520-7552 | lld:pubmed |
| pubmed-article:15386824 | pubmed:author | pubmed-author:NakamuraTsuka... | lld:pubmed |
| pubmed-article:15386824 | pubmed:author | pubmed-author:KoideHikaruH | lld:pubmed |
| pubmed-article:15386824 | pubmed:author | pubmed-author:EbiharaIsaoI | lld:pubmed |
| pubmed-article:15386824 | pubmed:author | pubmed-author:UedaYoshihiko... | lld:pubmed |
| pubmed-article:15386824 | pubmed:author | pubmed-author:KawagoeYasuhi... | lld:pubmed |
| pubmed-article:15386824 | pubmed:author | pubmed-author:MatsudaTakaha... | lld:pubmed |
| pubmed-article:15386824 | pubmed:copyrightInfo | Copyright (c) 2004 John Wiley & Sons, Ltd. | lld:pubmed |
| pubmed-article:15386824 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15386824 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:15386824 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15386824 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15386824 | pubmed:pagination | 39-43 | lld:pubmed |
| pubmed-article:15386824 | pubmed:meshHeading | pubmed-meshheading:15386824... | lld:pubmed |
| pubmed-article:15386824 | pubmed:meshHeading | pubmed-meshheading:15386824... | lld:pubmed |
| pubmed-article:15386824 | pubmed:meshHeading | pubmed-meshheading:15386824... | lld:pubmed |
| pubmed-article:15386824 | pubmed:meshHeading | pubmed-meshheading:15386824... | lld:pubmed |
| pubmed-article:15386824 | pubmed:meshHeading | pubmed-meshheading:15386824... | lld:pubmed |
| pubmed-article:15386824 | pubmed:meshHeading | pubmed-meshheading:15386824... | lld:pubmed |
| pubmed-article:15386824 | pubmed:meshHeading | pubmed-meshheading:15386824... | lld:pubmed |
| pubmed-article:15386824 | pubmed:meshHeading | pubmed-meshheading:15386824... | lld:pubmed |
| pubmed-article:15386824 | pubmed:meshHeading | pubmed-meshheading:15386824... | lld:pubmed |
| pubmed-article:15386824 | pubmed:meshHeading | pubmed-meshheading:15386824... | lld:pubmed |
| pubmed-article:15386824 | pubmed:meshHeading | pubmed-meshheading:15386824... | lld:pubmed |
| pubmed-article:15386824 | pubmed:meshHeading | pubmed-meshheading:15386824... | lld:pubmed |
| pubmed-article:15386824 | pubmed:meshHeading | pubmed-meshheading:15386824... | lld:pubmed |
| pubmed-article:15386824 | pubmed:meshHeading | pubmed-meshheading:15386824... | lld:pubmed |
| pubmed-article:15386824 | pubmed:meshHeading | pubmed-meshheading:15386824... | lld:pubmed |
| pubmed-article:15386824 | pubmed:meshHeading | pubmed-meshheading:15386824... | lld:pubmed |
| pubmed-article:15386824 | pubmed:articleTitle | Silent cerebral infarction in patients with type 2 diabetic nephropathy. Effects of antiplatelet drug dilazep dihydrochloride. | lld:pubmed |
| pubmed-article:15386824 | pubmed:affiliation | Department of Medicine, Shinmatsudo Central General Hospital, Chiba, Japan. | lld:pubmed |
| pubmed-article:15386824 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15386824 | pubmed:publicationType | Clinical Trial | lld:pubmed |
